KRAS and neoplasm: This mutation analysis has revealed the distribution patterns of missense mutations, C-to-T base substitutions, and key driver genes (such as APC, TP53, and KRAS) across different risk groups, providing molecular-level evidence for tumor prognosis stratification, personalized therapy, and biomarker development.